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Activating gene rearrangements of anaplastic lym-
phoma kinase (ALK) have been identiﬁed as driver
mutations in non-small-cell lung cancer, inﬂamma-
tory myoﬁbroblastic tumors, and other cancers.
Crizotinib, a dual MET⁄ALK inhibitor, has demon-
strated promising clinical activity in patients with
non-small-cell lung cancer and inﬂammatory myo-
ﬁbroblastic tumors harboring ALK translocations.
Inhibitors of driver kinases often elicit kinase
domain mutations that confer resistance, and such
mutations have been successfully predicted using
in vitro mutagenesis screens. Here, this approach
was used to discover an extensive set of ALK muta-
tions that can confer resistance to crizotinib. Muta-
tions at 16 residues were identiﬁed, structurally
clustered into ﬁve regions around the kinase active
site, which conferred varying degrees of resistance.
The screen successfully predicted the L1196M,
C1156Y, and F1174L mutations, recently identiﬁed
in crizotinib-resistant patients. In separate studies,
we demonstrated that crizotinib has relatively mod-
est potency in ALK-positive non-small-cell lung can-
cer cell lines. A more potent ALK inhibitor, TAE684,
maintained substantial activity against mutations
that conferred resistance to crizotinib. Our study
identiﬁes multiple novel mutations in ALK that may
confer clinical resistance to crizotinib, suggests
that crizotinib’s narrow selectivity window may
underlie its susceptibility to such resistance and
demonstrates that a more potent ALK inhibitor may
be effective at overcoming resistance.
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Chromosomal translocations of anaplastic lymphoma kinase (ALK),
originally identified in anaplastic large cell lymphoma (1), have now
been found in multiple tumor types, including inflammatory myofib-
roblastic tumors (IMT), and in 3–7% of non-small-cell lung cancers
(NSCLC) (2,3). Activating mutations and ALK gene amplifications
have also been detected in neuroblastomas (4). Preclinical studies
demonstrate that ALK inhibition induces apoptosis and tumor
regression in models of ALK-expressing tumors, identifying ALK as
a driver mutation and underscoring its potential as a therapeutic
target (5). Recently reported data from a phase 1 trial of crizotinib
(PF-02341066), a dual MET⁄ALK inhibitor (6) in ALK-positive patients
with NSCLC, revealed significant clinical efficacy (7). Combined with
a response in a patient with ALK-positive IMT (8), these data pro-
vide clinical validation of ALK as a target and proof-of-concept for
the targeted use of ALK inhibitors in ALK-driven tumors.
Treatment for tumors expressing driver kinases with targeted inhibi-
tors commonly leads to acquired resistance because of point muta-
tions in the kinase domain. In vitro accelerated mutagenesis
screens are powerful methods for identifying such mutations (9,10)
and have successfully predicted and recapitulated the spectra of
mutations observed clinically – for example, following the treatment
for chronic myeloid leukemia (CML) with different BCR-ABL inhibi-
tors (10). In this study, we conducted a mutagenesis screen to iden-
tify the potential resistance mechanisms to crizotinib in ALK-driven
tumors and determined whether a more potent ALK inhibitor,
TAE684 (11), could overcome resistance.
Methods and Materials
Cell lines and reagents
H2228, H838, and H23 NSCLC lines were obtained from the Ameri-
can Type Culture Collection (ATCC) and Ba⁄F3 cells from Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ). ATCC cell
lines were authenticated by ATCC's routine Cell Biology Program and
were used within 6 months of receipt. Ba⁄F3 cells were used within
6 months of receipt from DSMZ that authenticates human cell lines
by routine multiparameter methods prior to accession. H3122 cells
were obtained from NCI with no further authentication made. Crizotinib
and TAE684 (Figure S1) were synthesized at ARIAD Pharmaceuticals.
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In vitro cell growth, viability, and signaling
Cells were treated with crizotinib, TAE684, or vehicle (DMSO) for 72 h.
The effect on NSCLC growth was assessed using CyQuant (Invitrogen).
The concentration causing 50% growth inhibition (GI50) was deter-
mined by subtracting the cell count at time zero and plotting relative
to vehicle-treated cells. The effect on Ba⁄F3 cell viability (IC50) was
assessed using CellTiter-96 AQueous One (Promega, Madison, WI,
USA) and plotting viable cells relative to vehicle-treated cells.
Cell lysates prepared after 2-h treatment with compound were ana-
lyzed by immunoblotting, using antibodies against p-ALK
Y1604, total-
ALK, p-STAT3
Y705, p-AKT
S473, p-ERK1⁄2
T202 ⁄ Y204, p-S6P
T240 ⁄ 244,o r
by PathScan Sandwich ELISA against p-ALK
Y1604 and total-ALK (Cell
Signaling, Danvers, MA, USA).
EML4-ALK cloning and generation of cell lines
The native EML4-ALK variant 1 gene (Genbank: BAF73611.1; BlueSky
Biotech, Worcester, MA, USA) was cloned into the retroviral vector
pMSCV-Neo (Clontech, Mountain View, CA, USA), which was intro-
duced into Ba⁄F3 cells by retroviral transduction. After the selection,
cells were grown in the absence of IL-3. Plasmids encoding specific
EML4-ALK mutations were generated with the QuikChange site-
directed mutagenesis kit (Stratagene, Santa Clara, CA, USA).
In vitro mutagenesis screen
Ba⁄F3 cells expressing native EML4-ALK were treated overnight
with 100 lg⁄mL N-ethyl-N-nitrosourea (ENU; Sigma Aldrich, St.
Louis, MO, USA) and then distributed into 96-well plates containing
250, 500, 720, 1000, 1440, or 2000 nM crizotinib. The cells were
grown in standard growth medium, without IL-3, for 5 weeks. Cells
from the wells containing substantial outgrowth were expanded
under the original selection conditions, genomic DNA extracted, and
the ALK kinase region sequenced by Taq DyeDeoxy Terminator Cycle
Sequencing (Applied Biosystems, Carlsbad, CA, USA).
Model of crizotinib bound to ALK
A homology model of ALK was built based on the crystal structure
of activated insulin kinase (PDB code: 1ir3) using PRIME (v2.0; Schro-
dinger). Crizotinib was docked into ALK using GLIDE SP (v5.0; Schro-
dinger) with postdocking minimization and the top-scoring pose
chosen for further analysis.
Subcutaneous tumor models
H3122 or Ba⁄F3 cells expressing EML4-ALK were implanted into the
right flank of female Severe Combined Immunodeficiency (SCID)
Beige mice. Crizotinib or vehicle (water) was administered once daily
by oral gavage and mean tumor volume (L · W
2 · 0.5) calculated
for each group. Tumor growth inhibition (TGI) or regression (TR) was
calculated as follows: TGI = (1 ) DT⁄DC) · 100 was used when
DT > 0, where DT and DC represent the mean tumor volume
changes in treatment and control groups, respectively. When DT <0 ,
the formula TR = (DT⁄Ti) · 100 was used where Ti is the mean
tumor volume for the group at the start of treatment. Tumor mea-
surement data were analyzed with a one-way ANOVA test (GRAPHPAD
PRISM, La Jolla, CA, USA). Statistical significance was determined
using Dunnett's test. P-ALK levels were measured in homogenized
tumors by ELISA. Crizotinib concentrations in plasma were deter-
mined by LC⁄MS⁄MS.
Results
To understand the potential impact of resistant mutations on crizoti-
nib efficacy, we first characterized its activity in in vitro and in vivo
models of NSCLC. In H3122 cells, which express EML4-ALK variant
1, crizotinib inhibited ALK phosphorylation (p-ALK) with an IC50 of
43 nM and cell growth with a GI50 of 62 nM (Figure 1A and Table 1).
This was accompanied by inhibition of p-ERK and p-S6P, although
with minimal effects on STAT3 phosphorylation. Similar results were
obtained with H2228 cells, which express EML4-ALK variant 3 (12).
By contrast, IC50 values for two ALK-negative NSCLC cell lines were
>1000 nM (Table 1). These data establish that crizotinib differentially
inhibits the growth of EML4-ALK NSCLC cell lines relative to ALK-
negative cells with approximately 10- to 20-fold selectivity.
We also characterized the activity of crizotinib in a mouse H3122
xenograft model. Once daily oral administration of 25, 50, or
A
B
Figure 1: Crizotinib inhibits signaling and proliferation in EML4-
ALK-dependent NSCLC cell lines. (A) immunoblot analysis of p-ALK
and downstream signaling in H3122 cells treated with crizotinib. (B)
In vivo efficacy of crizotinib in an H3122 subcutaneous xenograft
model. Mean tumor volume €SEM is plotted.
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dose-dependent manner, with 14% tumor regression observed as
the best response to treatment (Figure 1B).
To identify kinase domain mutants resistant to crizotinib, we first
created a Ba⁄F3 cell line expressing native (unmutated) EML4-ALK
variant 1. This cell line was inhibited by crizotinib with an IC50 of
132 nM, representing a selectivity differential of ninefold over
parental Ba⁄F3 cells (Table 2). These assays guided us to use a
crizotinib concentration range in our mutagenesis screens of 250–
2000 nM.B a⁄F3 cells expressing native EML4-ALK were exposed to
the DNA-modifying agent ENU, cultured in 96-well plates in the
presence of crizotinib dilutions and monitored for cell growth.
Growth was observed in all wells containing 250 nM crizotinib.
Approximately, 60% of wells at 500 nM crizotinib showed out-
growth. At higher concentrations (720, 1000, and 1440 nM), cell
growth was observed in progressively fewer wells, with the only
concentration showing no outgrowth being 2000 nM.
Sequencing identified a total of 422 mutations representing amino
acid exchanges at 16 different sites (Figure 2A). The spectrum of
mutations was narrowed with increasing crizotinib concentrations,
in terms of both the sites modified and the number of alternative
amino acids identified at each position. Mutations at 15 different
sites were detected at 500 nM crizotinib, eight sites at 720 nM, six
sites at 1000 nM, and two sites at 1440 nM. The mutated residues
identified at the highest crizotinib concentrations in our screen were
C1156, I1171, F1174, L1196, S1206, and G1269. Similar results
were obtained in two additional experiments.
Interestingly, one of the residues most frequently mutated in our
screen, F1174, is also one of the most frequently identified posi-
tions for activating mutations in neuroblastoma (13). The same is
true for the residue R1275 of ALK; yet, mutations at this site were
not recovered in our screen. Consistent with this, we found that
the introduction of R1275Q into EML4-ALK had no negative impact
on sensitivity to crizotinib (IC50 4 7€8n M).
We selected the ten most frequently identified mutants, each at a
different residue, for further analysis (Table 2). As expected, the
IC50 values for viability of Ba⁄F3 cells expressing these mutants
were all above that for Ba⁄F3 cells expressing native EML4-ALK,
with IC50s ranging from 231 to 981 nM. The three most resistant
mutants, L1196M, S1206R, and G1269S, all had IC50s within two-
fold of parental, ALK-negative, Ba⁄F3 cells (IC50 1176 nM). There
was no evidence that the mutations increased the basal activity of
ALK as assessed by levels of p-ALK and downstream signaling pro-
teins (Figure 2C). However, the ability of crizotinib to inhibit ALK
Table 1: Inhibitory activity of
crizotinib and TAE684 on ALK-posi-
tive and ALK-negative NSCLC lines
Cell line ALK status
Crizotinib TAE684
Cell growth
(GI50, nM)
p-ALK
(IC50,n M)
Cell growth
(GI50, nM)
p-ALK
(IC50,n M)
H3122 EML4-ALK v1 62 € 18 43 € 37 1.5 € 0.6 1.0
H2228 EML4-ALK v3a⁄3b 121 € 61 55 € 4 3.8 € 2 3.7
H838 ALK negative 1307 € 270 ND 406 € 217 ND
H23 ALK negative 1773 € 743 ND 618 € 283 ND
ND, not determined.
Table 2: Inhibitory activity of crizotinib and TAE684 on Ba⁄F3 cells expressing EML4-ALK mutants
Ba⁄F3 line
Crizotinib TAE684
Viability (IC50s, nM) p-ALK (IC50,n M) Viability (IC50,n M) p-ALK (IC50,n M)
ENU clone
a Reintroduced ENU clone ENU clone ENU clone
Parental
b 1176 € 282 N⁄AN ⁄A 1283 € 348 N⁄A
Native EML4-ALK 132 € 45 N⁄A 102 € 70 8 € 1 5 € 3.5
T1151K 231 € 106 152 € 48 ND ND ND
L1152V 237 € 25 162 € 89 ND ND ND
C1156Y 489 € 48 ND 408 € 67 37 € 5 11 € 6
I1171T 393 € 134 413 € 62 ND ND ND
F1174C 479 € 40 319 € 90 165 € 112 40 € 2 6.7 € 2.5
L1196M 981 € 113 1215 € 708 1162 € 209 20 € 3 3.3 € 0.5
S1206R 681 € 176 728 € 362 356 € 173 80 € 9 16 € 11
E1210K 318 € 143 297 € 92 ND ND ND
F1245C 425 € 100 269 € 194 ND ND ND
G1269S 953 € 213 1196 € 649 1366 € 52 33 € 9 35 € 1
aENU clone: Ba⁄F3 cells obtained from the crizotinib mutagenesis screen.
bGrown in the presence of 10 ng⁄mL IL-3.
ND, not determined; N⁄A, not applicable; ALK, anaplastic lymphoma kinase.
Crizotinib-Resistant EML4-ALK Mutations
Chem Biol Drug Des 2011; 78: 999–1005 1001A
B
C
Zhang et al.
1002 Chem Biol Drug Des 2011; 78: 999–1005phosphorylation was substantially reduced in all mutants tested,
with IC50s >1000 nM for L1196M and G1269S (Table 2). A similar
impairment was seen on the ability of crizotinib to inhibit down-
stream signaling in cells expressing the L1196M mutant (Fig-
ure S2A). We verified that crizotinib resistance was solely
dependent on the mutations by analyzing Ba⁄F3 cell lines express-
ing mutant EML4-ALK fusions generated by site-directed mutagene-
sis and observing similar results (Table 2, 'Reintroduced').
The 16 mutations are located around the kinase active site and can
be categorized into five groups, involved in either direct or indirect
contacts with crizotinib. As shown in Figure 2B, group 1 is located
around the gatekeeper position, group 2 is located around the
kinase hinge region, group 3 is located near the ribose binding
pocket, group 4 is located at the loop of the N-terminus of a-helix
C, and group 5 is located in the vicinity of the kinase DFG (Asp-
Phe-Gly) motif of the activation loop. The three mutations that con-
ferred the strongest resistance were the L1196M gatekeeper resi-
due, S1206R at the solvent front, and G1269S near the DFG motif.
We characterized the sensitivity of these three mutants in mouse
xenograft studies (Figure 3A). Ba⁄F3 cells expressing native EML4-
ALK grew robustly as subcutaneous xenografts in SCID mice. Daily
oral treatment of these mice with crizotinib at 100 mg⁄kg induced
a modest tumor growth inhibition of 33%, which was not statisti-
cally significant (p > 0.05), and 200 mg⁄kg [the highest reported
daily oral dose for crizotinib in mice (14)] induced complete regres-
sions by 12 days of treatment. However, analogous Ba⁄F3 xeno-
grafts expressing L1196M, S1206R, or G1269S mutants were
completely insensitive to these doses, with no statistically signifi-
cant changes in tumor growth rate.
In pharmacodynamic studies (Figure 3B), xenografts expressing
native EML4-ALK exhibited a 60–70% inhibition in p-ALK levels at
6 h postdose, with more pronounced inhibition at 24 h. By contrast,
p-ALK levels were reduced by approximately 25–35% at 6 h in
tumors expressing L1196M or S1206R, with a partial recovery at
24 h. There was no significant inhibition in tumors expressing the
G1269S mutation. Drug exposure was similar in all models, confirm-
A
B
Figure 3: Crizotinib is not efficacious in mouse Ba⁄F3 xenograft models expressing EML4-ALK mutants. (A) In vivo efficacy of crizotinib in
EML4-ALK-driven Ba⁄F3 models. Mean tumor volume €SEM was plotted. (B) PK⁄PD analysis after treating tumor-bearing mice with a single
dose of vehicle (V, for 6 h) or 200 mg⁄kg crizotinib.
Figure 2: Spectrum of EML4-ALK mutations recovered in a mutagenesis screen. (A) resistant clones recovered from ENU-treated Ba⁄F3
cells expressing native EML4-ALK cultured with indicated concentrations of crizotinib. Each bar represents the relative percentage of the indi-
cated EML4-ALK kinase domain mutant among recovered clones. The percentage of wells surveyed that contained outgrowth is indicated. (B)
position of mutations in a model of crizotinib (shown in yellow) bound to the ALK kinase domain. (C) immunoblot analysis of p-ALK and down-
stream signaling in Ba⁄F3 cells carrying native and mutant variants of EML4-ALK.
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because of the inadequate target inhibition.
TAE684 is a previously described ALK inhibitor (11) that we have con-
firmed to be substantially more potent and selective than crizotinib
in ALK-driven NSCLC models (Table 1). TAE684 inhibited the viability
of Ba⁄F3 cells expressing native EML4-ALK (IC50 8n M) or the five
mutants that conferred the greatest resistance to crizotinib (IC50so f
20–80 nM) all with substantial selectivity over parental, ALK-negative
Ba⁄F3 cells (IC50 1283 nM; Table 2). Potent inhibition of p-ALK and
downstream signaling was also observed (Table 2; Figure S2).
Discussion
In this study, we have used an accelerated mutagenesis strategy to
identify an extensive set of mutations in ALK that can confer
resistance to crizotinib. Alterations at 16 different amino acids were
observed, with three of them, L1196M, S1206R and G1269S,
rendering cells completely insensitive in mouse xenograft studies.
Interestingly, use of an alternative approach, in which an ALK-posi-
tive NSCLC cell line is exposed to increasing doses of crizotinib, led
to the identification of one mutation, L1196M, that could confer
resistance to crizotinib (15). Our results confirm that kinase domain
mutations are a potential mechanism for acquired resistance to criz-
otinib and identify a novel, sizable panel of specific candidate
mutations for correlation with clinical studies.
An important factor in the resistance susceptibility of crizotinib
appears to be its relatively narrow window of activity against ALK-
positive versus ALK-negative cell lines: a differential of approxi-
mately 10- to 20-fold in our studies (Tables 1 and 2). This means
that even modest potency reductions linked to single mutations
may abrogate the selective activity of the compound. Ultimately,
the range of ALK mutations observed clinically will depend on phar-
macologic considerations, such as drug exposure and target inhibi-
tion levels in patients. By analogy with CML (16), however, more
potent ALK inhibitors should be able to overcome crizotinib-resistant
mutants. Indeed, we show that a more potent and selective ALK
inhibitor, TAE684, maintains substantial activity against the muta-
tions that confer the greatest resistance to crizotinib, with all
mutants inhibited with at least 15-fold selectivity over ALK-negative
cells. Recently, three additional ALK inhibitors, AP26113 (15),
CH5424802 (17), and X-396 (18), have also be shown to be capable
of inhibiting the L1196M variant of ALK in preclinical studies. Con-
sistent with our observations regarding TAE684, each of these com-
pounds has also been shown to be a more potent and selective
inhibitor of ALK than crizotinib.
Most of the mutations can be rationalized based on structural anal-
ysis (Figure 2B). The L1196M gatekeeper mutation likely sterically
impedes crizotinib binding. S1206, located near the ribose binding
pocket of ATP, makes a contact with crizotinib, in the docked model,
that would be eliminated by the S1206R mutation. Finally, G1269
(with D1268) forms a small hydrophobic pocket that binds the 3-flu-
oro-2,6-dichlorophenyl group of crizotinib. This interaction would be
disrupted by the G1269S mutation. Other mutated residues likely
stabilize the conformation of the crizotinib contact residues, includ-
ing V1180 and R1181 (in contact with L1196); E1210 (in contact
with S1206); and D1268, F1174, F1245, I1171, Y1278, and E1241 (in
direct or indirect contact with G1269). The three residues in group
4 (T1151, L1152, and C1156) do not make direct contacts with criz-
otinib, but likely have indirect conformational roles. TAE684, on the
other hand, has limited molecular contact interactions with the
gatekeeper residue L1196 as well as with G1269 of the DFG motif,
according to the recently published crystal structure (19), and is
thus less susceptible to these two mutations. However, TAE684 is
quite sensitive to the S1206R mutation. Analysis of the crystal
structure indicates that the mutated arginine 1206 is likely to form
a stabilized side chain conformation by interacting with its neigh-
boring two acidic residues (D1203 and E1210), and such a confor-
mation may be incompatible with the optimized binding pose of
TAE684 in the ALK protein.
Several isolated mutations were at positions where activating muta-
tions have previously been identified in ALK-expressing neuroblas-
toma (F1174, T1151, I1171, F1245, and Y1278) (13,20,21). In
particular, F1174 is one of the most frequently mutated residues in
neuroblastoma, and the mutations of F1174 to Cys, Val, Ile, and Leu
were observed in our screen. F1174 is at the loop C-terminal to the
alpha-helix C and forms a hydrophobic patch with neighboring resi-
dues including F1241 of the DFG motif. F1174L may therefore stabi-
lize an active conformation that is both more oncogenic and less
favored for crizotinib binding.
This screen has several potential limitations. Ba⁄F3 cells in vitro
are unlikely to faithfully recapitulate the cellular context of ALK-dri-
ven primary human tumors. Additionally, mutation-focused screens
do not probe alternative resistance mechanisms, such as gene
amplification or upregulation of parallel signaling pathways. Never-
theless, such screens have proved highly predictive with other kin-
ases (10). Most importantly, the clinical relevance of our findings is
supported by the recent identification, after completion of our study,
of the L1196M and C1156Y mutations from a patient with NSCLC
with acquired resistance to crizotinib (22) and a separate report
identifying the F1174L mutation in an IMT patient with similar
acquired resistance (23). Our studies suggest multiple additional
mutations that have the potential to confer resistance to crizotinib
in patients and provide guidance for the rational design and optimi-
zation of potent and selective second generation drugs that may be
able to overcome ALK-based mechanisms of resistance.
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